Is venetoclax in combination with low-dose cytarabine a safe regimen for the treatment of AML?
Andrew Wei • 24 Jun 2017
Impact of MMRD and ELN genetic classification in outcomes for patients with AML underoging alloHCT
Muhammad Husnain • 17 Feb 2021
Flotetuzumab as salvage therapy for primary induction failure and early AML
Ibrahim Aldoss • 11 Feb 2021